From: DNA methylation gene-based models indicating independent poor outcome in prostate cancer
Model A:Gene-Only | Model B:Genes + PSA | Model C:Gleason + PSA | Model D:Final model | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Variable | HR (95% CI) | χ2 | P -value | HR (95% CI) | χ2 | P -value | HR (95% CI) | χ2 | P -value | HR (95% CI) | χ2 | P -value |
Gleason | -b | - | - | - | - | - | 2.20 (1.82, 2.67) | 66.3 | 3.3*10-16 | 2.72 (2.09, 3.53) | 56.3 | 6.4*10-14 |
PSA | - | - | - | 1.27 (1.18, 1.38) | 36.5 | 1.5*10-9 | 1.27 (1.17, 1.37) | 34.9 | 3.5*10-9 | 1.23 (1.13, 1.34) | 24.7 | 6.7*10-7 |
DPYS | 1.12 (1.02, 1.24) | 5.8 | 0.016 | 1.12 (1.02, 1.24) | 5.3 | 0.021 | - | - | - | 1.13 (1.03, 1.25) | 6.4 | 0.012 |
HSPB1 | 0.88 (0.78, 0.99) | 4.6 | 0.032 | - | - | - | 2.39 (1.15, 4.97) | 5.5 | 0.019 | |||
Gleason x HSPB1 a | - | - | - | - | - | - | - | - | - | 0.89 (0.81, 0.97) | 6.2 | 0.012 |
CCND2 | - | - | - | 0.86 (0.75, 0.98) | 5.1 | 0.024 | ||||||
MAL | 1.19 (1.05, 1.34) | 7.6 | 0.006 | 1.17 (1.03, 1.34) | 5.7 | 0.017 | - | - | - | |||
GSTP1 | 1.15 (1.03, 1.27) | 6.6 | 0.010 | - | - | - | ||||||
TIG1 | 1.15 (1.03, 1.27) | 6.5 | 0.011 | - | - | - | ||||||
LR χ 2 (df) | 49.4 (3) | 76.6 (5) | 111.4 (2) | 125.6 (6) | ||||||||
Harrell’s c-index (se) | 0.716 (0.034) | 0.771 (0.034) | 0.831 (0.034) | 0.835 (0.034) | ||||||||
Gönen & Heller’s c-index c (se) | 0.696 (0.022) | 0.702 (0.019) | 0.738 (0.016) | 0.757 (0.017) |